Skip to main content
. 2016 Jun 3;11(6):e0156789. doi: 10.1371/journal.pone.0156789

Fig 1. Impact of BRCA1/2 P/LP variants on the DFS of BC patients with stage 0~III.

Fig 1

Kaplan-Meier survival analysis; P values calculated using a log-rank analysis. Estimated DFS of breast cancer patients with stage 0~III by BRCA status: (A) BRCA1/2 P/LP variants (germline or somatic); (B) BRCA1 and BRCA2 P/LP variants (germline or somatic); (C) Germline and somatic BRCA1/2 P/LP variants; (D) Germline BRCA1 and germline BRCA2 P/LP variants.